Reconstruction of human papillomavirus type 16-mediated early-stage neoplasia implicates E6/E7 deregulation and the loss of contact inhibition in neoplastic progression

Journal of Virology

Volumn 86, Issue 11, 2012, Pages 6358-6364

  Wechsler, Erin Isaacson ^a   Wang, Qian ^a   Roberts, Ian ^b   Pagliarulo, Emilio ^a   Jackson, Deborah ^a   Untersperger, Christina ^a   Coleman, Nick ^b   Griffin, Heather ^a   Doorbar, John ^a  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^b HUTCHISON MRC RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN E6; PROTEIN E7; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; REPRESSOR PROTEIN; VIRULENCE FACTOR;

ARTICLE; CANCER CLASSIFICATION; CELL CULTURE; CELL CYCLE PROGRESSION; CELL INTERACTION; CONTACT INHIBITION; CONTROLLED STUDY; DISEASE SEVERITY; EPITHELIUM TUMOR; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENOMIC INSTABILITY; HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; LOW GRADE SQUAMOUS INTRAEPITHELIAL LESION; NONHUMAN; ONCOGENE; PAPILLOMAVIRUS INFECTION; PHENOTYPE; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; UTERINE CERVIX CARCINOMA IN SITU; VIRAL EPISOME; VIRUS CARCINOGENESIS; VIRUS ENTRY; VIRUS GENE; VIRUS MORPHOLOGY; CARCINOMA IN SITU; IN VITRO STUDY; METABOLISM; PATHOGENICITY; UTERINE CERVIX TUMOR; VIROLOGY;

HUMAN PAPILLOMAVIRUS TYPE 16;

CARCINOMA IN SITU; CELLS, CULTURED; CONTACT INHIBITION; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; REPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS; VIRULENCE FACTORS;

EID: 84863593481     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.07069-11     Document Type: Article

References (23)

1. Allen-Hoffmann BL, et al. 2000. Normal growth and differentiation in a spontaneously immortalized near-diploid human keratinocyte cell line, NIKS. J. Invest. Dermatol. 114:444-455.
2. Davidson EJ, et al. 2003. Minichromosome maintenance (Mcm) proteins, cyclin B1 and D1, phosphohistone H3 and in situ DNA replication for functional analysis of vulval intraepithelial neoplasia. Br. J. Cancer 88:257-262.
3. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. 2004. Classification of papillomaviruses. Virology 324:17-27.
4. Doorbar J. 2006. Molecular biology of human papillomavirus infection and cervical cancer. Clin. Sci. (Lond.) 110:525-541.
5. Doorbar J, et al. 1997. Characterization of events during the late stages of HPV16 infection in vivo using high-affinity synthetic Fabs to E4. Virology 238:40-52.
6. Dyson N, Howley PM, Munger K, Harlow E. 1989. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934-937.
7. Foster N, et al. 2009. Molecular cytogenetic analysis of cervical squamous cell carcinoma cells demonstrates discordant levels of numerical and structural chromosomal instability and identifies 'selected' chromosome rearrangements. Cytogenet. Genome Res. 127:9-20.
8. Hafner N, et al. 2008. Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene 27:1610-1617.
9. Hillemanns P, Wang X. 2006. Integration of HPV-16 and HPV-18 DNA in vulvar intraepithelial neoplasia. Gynecol. Oncol. 100:276-282.
10. Khleif SN, et al. 1996. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc. Natl. Acad. Sci. U. S. A. 93:4350-4354.
11. Klaes R, et al. 1999. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res. 59:6132-6136.
12. Lambert PF, et al. 2005. Using an immortalized cell line to study the HPV life cycle in organotypic "raft" cultures. Methods Mol. Med. 119:141-155.
13. Laurson J, Raj K. Localisation of human papillomavirus 16 e7 oncoprotein changes with cell confluence. PLoS One 6:e21501.
14. Lechner MS, et al. 1992. Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J. 11:3045-3052.
15. Middleton K, et al. 2003. Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. J. Virol. 77:10186-10201.
16. Paavonen J, et al. 2007. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III doubleblind, randomised controlled trial. Lancet 369:2161-2170.
17. Paavonen J, et al. 2009. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:301-314.
18. Peh WL, Doorbar J. 2005. Detection of papillomavirus proteins and DNA in paraffin-embedded tissue sections. Methods Mol. Med. 119:49-59.
19. Peh WL, et al. 2002. Life cycle heterogeneity in animal models of human papillomavirus-associated disease. J. Virol. 76:10401-10416.
20. Szarewski A, et al. 19 August 2011. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. Int. J. Cancer [Epub ahead of print.] doi:10.1002/ijc.26362.
21. Takizawa S, et al. 2006. Human scribble, a novel tumor suppressor identified as a target of high-risk HPV E6 for ubiquitin-mediated degradation, interacts with adenomatous polyposis coli. Genes Cells 11: 453-464.
22. Williams GH, et al. 1998. Improved cervical smear assessment using antibodies against proteins that regulate DNA replication. Proc. Natl. Acad. Sci. U. S. A. 95:14932-14937.
23. Ziegert C, et al. 2003. A comprehensive analysis of HPV integration loci in anogenital lesions combining transcript and genome-based amplification techniques. Oncogene 22:3977-3984.